Phase 3CompletedAge-related condition

Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease

Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease

Sponsor
Technische Universität Dresden (Academic or other)
Enrollment
132 planned
Conditions
Parkinson's Disease
Interventions
Coenzyme Q10 Nanodispersion (Nanoquinone); Placebo
Ages
adults, older adults
Registry
NCT00180037

Full record on ClinicalTrials.gov

From the registry

This study was designed to evaluate the symptomatic effects of Coenzyme Q10 nanodispersed solution in middle-stage Parkinson's disease (PD) patients (Hoehn\&Yahr II to III). The treatment phase includes three months period of 300 mg Coenzyme Q10 per day or placebo. The primary outcome measure was the combined Unified Parkinson's Disease Rating Scale (UPDRS) Part II and III. The hypothesis of this study was that Coenzyme Q10 improves the energy status of the diseased dopaminergic neuronal cell type and thus producing more dopamine leading to an improvement of parkinsonian symptoms in PD patients.

Primary outcomes

  • Unified Parkinson's Disease Rating Scale (UPDRS) Part II and III

History

  1. Last registry update

  2. Registered

  3. Primary completion

  4. Started